Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Completed · Phase 2
Conditions studied: Pancreatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage III or stage IV pancreatic cancer that cannot be surgically removed.
Key facts
- Study ID
- NCT00003760
- Run by
- The University of Texas Health Science Center at San Antonio
- People needed
- 3
- Starts
- 1998-11-01
- Expected to finish
- 2000-05-01
- Last updated by the study team
- 2012-08-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Nebraska Medical Center — Omaha, Nebraska, United States
- Brooke Army Medical Center — Fort Sam Houston, Texas, United States
- San Antonio Cancer Institute — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.